scholarly journals Influence of ABCB1 C3435T gene polymorphisms on tumor response to neoadjuvant chemotherapy in locally advanced breast cancer patients from Northeastern Brazil.

2019 ◽  
Author(s):  
Diego de Aragão Bezerra ◽  
Jose Juvenal Linhares ◽  
Emmanuelle Coelho Noronha ◽  
Kaio César Simiano Tavares ◽  
André Saraiva Leão Marcelo Antunes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Locally Advanced Breast Cancer ◽  
Single Gene ◽  
Locally Advanced ◽  
Northeastern Brazil ◽  
P Value ◽  
Female Population ◽  
C3435t Polymorphism ◽  
Response To Neoadjuvant Chemotherapy

Abstract Background: Breast cancer (BC) is the most common tumor and the leading cause of cancer-related death among the female population worldwide. To evaluate the association between the ABCB1 C3435T single gene nucleotide polymorphisms (SNPs) with the response to neoadjuvant chemotherapy in women with breast cancer. Methods: This study included 32 female patients who received neoadjuvant chemotherapy. The polymorphisms were genotyped through real-time allele-specific polymerase chain reaction (PCR). The statistical analysis was performed using the Fisher's exact test or Pearson's chi-square test in the Statistical Package for Social Sciences (SPSS) version 20.0 software. Results: The genotypes found for the C3435T polymorphism were in Hardy-Weinberg equilibrium and their genotypic distributions were CC= 10 (31.1%), CT= 14 (43.8%), and TT= 08 (25.0%) with χ2: 0.86 and p-value > 0.05. Allele frequencies were C = 0.54 and T = 0.46. There were no significant statistical differences between genotypes considering the response to neoadjuvant chemotherapy and immunohistochemistry; the presence of the T allele was associated with worsen axillary status response to neoadjuvant chemotherapy. Conclusion: No definite association between the presence of C3435T polymorphism and the response to neoadjuvant chemotherapy was observed. Further studies in Brazil involving larger samples will contribute to validating the results of this study. Keywords: Breast cancer; Neoadjuvant Chemotherapy; Polymorphisms; Gene ABCB1

Association of the ABCB1 C3435T gene polymorphism (SNPs) with the response to neoadjuvant chemotherapy in women with breast cancer in northeastern Brazil

2020 ◽  
Vol 19 (2) ◽  
pp. 305
Author(s):  
Diego de Aragão Bezerra De Aragão Bezerra ◽  
José Juvenal Linhares ◽  
Emmanuelle Coelho Noronha ◽  
Kaio César Simiano Tavares ◽  
André Saraiva Leão Marcelo Antunes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Gene Polymorphism ◽  
Cancer Susceptibility ◽  
Northeastern Brazil ◽  
P Value ◽  
Chemotherapy Response ◽  
Female Population ◽  
C3435t Polymorphism ◽  
Response To Neoadjuvant Chemotherapy

<p><strong>Introduction</strong>: breast cancer (BC) is the most common tumor and the leading cause of cancer-related death among the female population<br />worldwide. Polymorphisms genetics of ABCB1 gene contributed to breast cancer susceptibility and interindividual differences in<br />chemotherapy response. <strong>Objectives</strong>: to evaluate the association between the ABCB1 C3435T gene polymorphism (SNPs) with the<br />response to neoadjuvant chemotherapy in women with breast cancer. <strong>Methodology</strong>: this study included 32 female patients who<br />received neoadjuvant chemotherapy. The polymorphisms were genotyped through real-time allele-specific polymerase chain reaction<br />(PCR). The statistical analysis was performed using the Fisher’s exact test or Pearson’s chi-square test in the Statistical Package for<br />Social Sciences (SPSS) version 20.0 software. <strong>Results</strong>: the genotypes found for the C3435T polymorphism were in Hardy-Weinberg<br />equilibrium and their genotypic distributions were CC= 10 (31.1%), CT= 14 (43.8%), and TT= 08 (25.0%) with χ2: 0.86 and p-value &gt;<br />0.05. Allele frequencies were C = 0.54 and T = 0.46. There were no significant statistical differences between genotypes considering the<br />response to neoadjuvant chemotherapy and immunohistochemistry; the presence of the T allele was associated with worsen axillary<br />status response to neoadjuvant chemotherapy. <strong>Conclusion</strong>: no definite association between the presence of C3435T polymorphism<br />and the response to neoadjuvant chemotherapy was observed. Further studies in Brazil involving larger samples will contribute to<br />validating the results of this study.</p>

scholarly journals Predicting Response to Neoadjuvant Chemotherapy in Women with Locally Advanced Breast Cancer in Kenya: Utility of Ki67

2021 ◽  
Vol 18 (1) ◽  
pp. 23-28
Author(s):  
Edwin Mogere ◽  
Joseph Githaiga ◽  
Francis Owilla ◽  
Mary Mungania ◽  
Daniel Ojuka
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Breast Cancer ◽  
Tumor Size ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Tumor Biology ◽  
Advanced Breast ◽  
P Value ◽  
Response To Neoadjuvant Chemotherapy

Background: Ki67 levels have been shown to have good predictive value in breast cancer treatment. There is paucity of data on Ki67 levels in predicting response to neoadjuvant chemotherapy (NACT) in Kenya. This study evaluated the utility of Ki67 in predicting response to NACT. Methods: This was a prospective observational study carried out at Kenyatta National Hospital between December 2017 and January 2019 onpatients with locally advanced breast cancer. We recruited 61 women through consecutive sampling technique. Data collected included patient demographics, pre-treatment tumor size, Ki67 levels and tumor biology. After 3 cycles of first-line chemotherapy, ultrasonography was used to determine response. Data were analyzed by SPSS for proportion of change in tumor size. The response was correlated with tumor biology and pretreatment levels of Ki67 using chisquare at a 95% confidence interval. A p-value <0.05 was considered statistically significant. Results: The response rate after 3 cycles of NACT was 39.4%, sensitivity and specificity of Ki67 levels were 70.8% and 43.2% respectively with a cut-off value of 32.5%. Conclusions: Ki67 was found to predict response in our context at a rate of 39.4% at 20% cutoff after 3 cycles. Keywords: Ki67, Breast cancer, Neoadjuvant chemotherapy

Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women

2011 ◽  
Vol 29 (2) ◽  
pp. 539-546 ◽  
Author(s):  
L. C. Singh ◽  
Anurupa Chakraborty ◽  
Ashwani K. Mishra ◽  
Thoudam Regina Devi ◽  
Nidhi Sugandhi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Indian Women ◽  
Predictive Role ◽  
Egfr Family ◽  
Response To Neoadjuvant Chemotherapy

Prediction of response to neoadjuvant chemotherapy in breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 20005-20005
Author(s):  
J. Hannemann ◽  
H. Halfwerk ◽  
A. Velds ◽  
C. Loo ◽  
E. Rutgers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Neoadjuvant Chemotherapy ◽  
Hormone Receptors ◽  
Locally Advanced Breast Cancer ◽  
Expression Patterns ◽  
Locally Advanced ◽  
Cdna Array ◽  
Steroid Hormone Receptors ◽  
Response To Neoadjuvant Chemotherapy

20005 Background: Neoadjuvant chemotherapy is increasingly employed in operable breast cancer. Our initial studies on a cDNA array platform failed to identify gene expression patterns predicting response to neoadjuvant chemotherapy in breast cancer patients (J Clin Oncol 23:3331, 2005). Now we included more patients and used oligo microarrays. Methods: Patients with operable or locally advanced breast cancer were included in a randomized phase II study or received neoadjuvant chemotherapy off protocol. All except 7 patients began chemotherapy with 3 courses of dose-dense adriamycin and cyclophosphamide (ddAC) and response was evaluated by MRI. Patients with a response and a HER2-positive tumor were then randomized between either 3 additional courses of ddAC or six weekly courses of carboplatin, paclitaxel and trastuzumab (CPT). Patients without response were switched to CPT. Patients with HER2-negative tumors were randomized between 3 courses of either ddAC or capecitabine and docetaxel (CD). After evaluation, patients without response were switched to the alternative treatment arm. From all patients 14G core needle biopsies were taken before treatment and total RNA was isolated. Amplified mRNA was labeled and hybridized to 35k human oligo microarrays from our microarray facility. Results: So far, 77 patients have been included into the study. From 48 of these, good quality RNA from tissue with >50% tumor cells was isolated. 43 patients had received ddAC as initial chemotherapy; 32 of these had not been switched to another regimen. In a training set containing 11 pathological complete remissions (pCR) and 9 non-responders (NR) we could separate these groups by using 20 genes in a supervised classification and a 9-step cross validation. These results could be validated in an independent set of 11 samples (6 pCR, 5 NR). From 10 out of 11 samples, response status could be predicted correctly, independent from the treatment regimen. Although ER-positive tumors have a lower pCR rate than ER-negative ones, the steroid hormone receptors were not present in the classifier. Conclusions: We conclude that it should be possible to identify a reliable gene expression profile associated with response to adriamycin based neoadjuvant chemotherapy in breast cancer. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document